Resveratrol supplementation reduces ACE2 expression in human adipose tissue

Adipocyte. 2021 Dec;10(1):408-411. doi: 10.1080/21623945.2021.1965315.

Abstract

Angiotensin converting enzyme-2 (ACE2) is the cell-surface receptor enabling cellular entry of SARS-CoV-2. ACE2 is highly expressed in adipose tissue (AT), rendering AT a potential SARS-CoV-2 reservoir contributing to massive viral spread in COVID-19 patients with obesity. Although rodent and cell studies suggest that the polyphenol resveratrol alters ACE2, human studies are lacking. Here, we investigated the effects of 30-days resveratrol supplementation on RAS components in AT and skeletal muscle in men with obesity in a placebo-controlled cross-over study. Resveratrol markedly decreased ACE2 (~40%) and leptin (~30%), but did neither alter angiotensinogen, ACE and AT1R expression in AT nor skeletal muscle RAS components. These findings demonstrate that resveratrol supplementation reduces ACE2 in AT, which might dampen SARS-CoV-2 spread in COVID-19.

Keywords: ACE2; Covid-19; Resveratrol; SARS-CoV-2; leptin; renin-angiotensin-system.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adipose Tissue / cytology
  • Adipose Tissue / metabolism*
  • Angiotensin-Converting Enzyme 2 / genetics
  • Angiotensin-Converting Enzyme 2 / metabolism*
  • COVID-19 / pathology
  • COVID-19 / virology
  • Cross-Over Studies
  • Dietary Supplements
  • Double-Blind Method
  • Down-Regulation / drug effects
  • Humans
  • Leptin / genetics
  • Leptin / metabolism
  • Male
  • Middle Aged
  • Obesity / drug therapy
  • Obesity / pathology
  • Placebo Effect
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / metabolism
  • Resveratrol / administration & dosage*
  • Resveratrol / pharmacology
  • SARS-CoV-2 / isolation & purification

Substances

  • AGTR1 protein, human
  • Leptin
  • Receptor, Angiotensin, Type 1
  • Angiotensin-Converting Enzyme 2
  • Resveratrol